CJC-1295 with DAC vs CJC/IPA Protocol
Well Studied vs Well Studied
monitor Mechanism-based · 47% Both CJC-1295 with DAC and CJC/IPA Protocol affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine).
Molecular Data
CJC-1295 with DAC CJC/IPA Protocol
Weight 3,647.28 Da N/A
Half-life 6-8 days —
Chain 30 amino acids N/A
Type GHRH analog with DAC Peptide combination (GHRH analog + GHS)
Key Benefits
CJC-1295 with DAC
01 Convenient weekly dosing
02 Sustained GH/IGF-1 elevation
03 6-8 day half-life
04 Significant body composition changes
CJC/IPA Protocol
01 Sustained GH elevation (6-8 days from CJC-1295)
02 Selective pulsatile release without cortisol suppression
03 Complementary dual-pathway optimization
04 Preservation of natural GH rhythm
05 Enhanced muscle protein synthesis and recovery
Dosing Protocols
CJC-1295 with DAC
1-2mg weekly / Once or twice weekly (e.g., Monday/Thursday for split dosing)
Conservative Anti-Aging 1mg Once weekly
Standard Protocol 2mg Once weekly
Split Dosing 1mg Twice weekly (Mon/Thu)
Loading Protocol 2mg first week, then 1mg Weekly
CJC/IPA Protocol
200-300mcg of each peptide (CJC-1295 and Ipamorelin) / Once daily, preferably in the evening
General Health Optimization 200mcg each (0.2mL if 1mg/mL) Once daily
Performance Enhancement 250mcg each (0.25mL if 1mg/mL) Once daily
Recovery Optimization 300mcg each (0.3mL if 1mg/mL) Once daily
Conservative Approach 150mcg each (0.15mL if 1mg/mL) 5 days per week
Side Effects
CJC-1295 with DAC
Water retention
Joint pain
Carpal tunnel symptoms
CJC/IPA Protocol
Water retention and joint swelling
Carpal tunnel syndrome (numbness/tingling)
Mild blood glucose elevation
Injection site irritation with improper rotation
Contraindications
Diabetes history
Cancer history
Predisposed sleep apnea
Cancer history or active malignancy
Severe diabetes requiring tight glucose control
Carpal tunnel syndrome or nerve compression disorders
Research Evidence
CJC-1295 with DAC CJC/IPA Protocol
Status Well Studied Well Studied
References 4 studies 4 studies
Latest 2025 June 2024
FDA Approved No No
Full CJC-1295 with DAC profile Full CJC/IPA Protocol profile CJC-1295 with DAC calculator CJC/IPA Protocol calculator
More comparisons: BPC-157
This comparison is for educational and research purposes only. Consult a healthcare professional before use.